QATAR UNIVERSITY

Apabetalone Shows Promise as Epigenetic Therapy for Chronic Diseases

8 months ago

• Qatar University researchers highlight Apabetalone's potential as an epigenetic therapy for treating various chronic diseases by targeting gene expression. • Apabetalone, a unique inhibitor with FDA breakthrough therapy designation (excluding oncology), impacts multiple biological functions involved in disease development. • Preclinical studies suggest Apabetalone's efficacy in cardiovascular, renal, neurological, viral, and cancer disorders, warranting further investigation in clinical trials. • The research underscores the importance of epigenetic treatments in regulating gene transcription and improving cell communication for enhanced health outcomes.